ArticlePharmaceutical research2026
Transnasal Administration of Surfactant Aerosol to the Lungs of Infants Using Direct Interfaces - Lessons Learned from Computational Fluid Dynamics.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeDirect-to-infant (D2I) transnasal aerosol surfactant therapy (AST) offers a promising non-invasive alternative for treating neonatal respiratory distress syndrome (RDS). However, achieving high lung delivery efficiency with dry powder inhalers (DPIs) requires careful optimization of complex fluid-particle interactions. This study used computational fluid dynamics (CFD) to optimize an Infant Air‑Jet Dry Powder Aerosol Delivery System (iDP‑ADS) and derive transferable design principles.
methodsA CFD model of the iDP‑ADS coupled to a 31‑week preterm nose‑throat geometry was validated against in vitro measurements. Sensitivity analyses evaluated modeling assumptions (steady‑state vs. transient, monodisperse vs. polydisperse) and critical design parameters influencing aerosol delivery, such as upstream air volume, interface geometry, temporal aerosol emission profiles, and actuation flow rates.
resultsThe CFD model demonstrated strong in vitro agreement (2.8% mean absolute difference). Regarding modeling: standard simplifications, particularly steady-state approximations, overpredicted lung transmission (~24%), establishing the necessity of high-fidelity transient simulations with polydisperse aerosols. Regarding aerosol delivery: integrating an upstream air volume created "hydrodynamic shielding," reducing relative interface losses by up to 50%. A 10 mm diffusive path length and 20° (inward and downward) prong alignment balanced jet dissipation while minimizing nasal deposition. Front-loading of aerosol emission prevented entrapment of 10-14% of the dose in anatomical dead space. An optimal system-specific actuation flow rate of 3 L/min achieved ~53.5% aerosol lung transmission, balancing aerosolization efficiency against turbulence-driven transport losses.
conclusionsHigh-efficiency transnasal AST requires balancing often competing aerosol generation physics, transport behavior, and clinical constraints. This study highlights CFD as a vital design tool, providing key lessons to inform future modeling and practical interface development.
Indexed as
Identifiers
42687071What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.